Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Biochemistry ; 48(35): 8466-72, 2009 Sep 08.
Artículo en Inglés | MEDLINE | ID: mdl-19642650

RESUMEN

The innate immune response to infection or injury involves an antigen-antibody triggered classical pathway (CP) of complement activation, in which soluble and cell surface plasma proteins cooperatively effect elimination of foreign organisms and damaged host cells. However, protracted or dysfunctional complement activation can lead to inflammatory diseases. Complement component 2 bound to C4b is cleaved by classical (C1s) or lectin (MASP2) proteases to produce C4bC2a, a very short-lived C3 convertase (t(1/2) 2 min) that in turn cleaves C3 to C3a and C3b, leading ultimately to formation of Membrane Attack Complex (MAC) and lysis of bacteria and damaged cells. C2 has the same serine protease domain as C4bC2a but in an inactive zymogen-like conformation, requiring cofactor-induced conformational change for activity. Here, we show that C2 has catalytic protease activity in its own right above pH 7, in the absence of cofactor, processing C3 and C3-derived chromogenic peptide fragments. In contrast to the instability of C3 convertase (t(1/2) 2 min, pH 7), the C2 enzyme is indefinitely stable under alkaline conditions, facilitating studies of its catalytic properties and development of small molecule inhibitors. We characterize the catalytic activity of C2 against C3 and short paranitroanilide peptide substrates, and identify potent small molecule inhibitors of C2 that also inhibit classical pathway C3 convertase, MAC formation, and hemolysis of sensitized sheep erythrocytes. These results provide a new avenue and valuable new insights to inhibiting CP complement activation relevant to inflammatory diseases.


Asunto(s)
Complemento C2/farmacología , Convertasas de Complemento C3-C5/antagonistas & inhibidores , Vía Clásica del Complemento , Serina Endopeptidasas/efectos de los fármacos , Animales , Activación de Complemento , Complemento C2/química , Complemento C2b/metabolismo , Complemento C3/metabolismo , Convertasas de Complemento C3-C5/metabolismo , Complemento C3b/metabolismo , Complemento C4b/metabolismo , Complejo de Ataque a Membrana del Sistema Complemento , Eritrocitos , Humanos , Concentración de Iones de Hidrógeno , Conformación Proteica , Pliegue de Proteína , Serina Endopeptidasas/metabolismo , Ovinos
2.
Exp Cell Res ; 310(1): 54-65, 2005 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-16112669

RESUMEN

Complement C2 receptor inhibitor trispanning (CRIT) is a receptor for the second component of complement and is found in various tissues and hemopoietic cells. On binding to CRIT, C2 cannot be activated to potentially form a variant-C3 convertase as it is rendered non-cleavable by C1s. CRIT thus limits the amount of C3 convertase formed on the cell surface. In this study we have shown, using flow cytometry and immunofluorescence microscopy, that human CRIT undergoes endocytosis from the plasma membrane. The endocytosis, possibly ligand mediated, occurs via clathrin-coated pits as it can be inhibited by prior incubation of cells in hypertonic medium or with chlorpromazine, at 37 degrees C. However, inhibition of endocytosis was not possible after treatment with nystatin, or filipin, inhibitors of caveolae/raft-dependent endocytosis. In the presence of C2 alone, CRIT associates with the adapter protein, beta-arrestin-2, and whether in association with C2 or not, then appears in the perinuclear region, but does not appear to be translocated into the nucleus. Apart from the C3aR and C5aR that internalize the anaphylatoxic peptides, this is the first report of the internalization via the clathrin pathway of a receptor for a complement serum protein.


Asunto(s)
Proteínas Portadoras/metabolismo , Vesículas Cubiertas por Clatrina/fisiología , Proteínas Inactivadoras de Complemento/fisiología , Endocitosis/fisiología , Transducción de Señal/fisiología , Arrestinas/metabolismo , Proteínas Portadoras/farmacología , Vesículas Cubiertas por Clatrina/química , Colchicina/farmacología , Complemento C2/farmacología , Proteínas Inactivadoras de Complemento/farmacología , Filipina/farmacología , Humanos , Células Jurkat , Ligandos , Nistatina/farmacología , Fosfoproteínas/metabolismo , Fosforilación , Tirosina/química
3.
J Neurophysiol ; 93(1): 178-88, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15604462

RESUMEN

We show that activation of postsynaptic inositol 1,4,5-tris-phosphate receptors (IP(3)Rs) with the IP(3)R agonist adenophostin A (AdA) produces large increases in AMPA receptor (AMPAR) excitatory postsynaptic current (EPSC) amplitudes at hippocampal CA1 synapses. Co-perfusion of the Ca(2+) chelator bis-(o-aminophenoxy)-N,N,N',N'-tetraacetic acid strongly inhibited AdA-enhanced increases in EPSC amplitudes. We examined the role of AMPAR insertion/anchoring in basal synaptic transmission. Perfusion of an inhibitor of synaptotagmin-soluble n-ethylmaleimide-sensitive factor attachment protein (SNAP) receptor SNARE-mediated exocytosis depressed basal EPSC amplitudes, whereas a peptide that inhibits GluR2/3 interactions with postsynaptic density-95 (PDZ) domain proteins glutamate receptor interacting protein (GRIP)/protein interacting with C-kinase-1 (PICK1) enhanced basal synaptic transmission. These results suggest that constitutive trafficking and anchoring of AMPARs help maintain basal synaptic transmission. The regulation of postsynaptic AMPAR trafficking involves synaptotagmin-SNARE-mediated vesicle exocytosis and interactions between AMPARs and the PDZ domains in GRIP/PICK1. We show that inhibitors of synaptotagmin-SNARE-mediated exocytosis, or interactions between AMPARs and GRIP/PICK1, attenuated AdA-enhanced increases in EPSC amplitudes. These results suggest that IP(3)R-mediated Ca(2+) release can enhance AMPAR EPSC amplitudes through mechanisms that involve AMPAR-PDZ interactions and/or synaptotagmin-SNARE-mediated receptor trafficking.


Asunto(s)
Adenosina/análogos & derivados , Calcio/metabolismo , Ácido Egtácico/análogos & derivados , Hipocampo/citología , Neuronas/metabolismo , Receptores de Glutamato/metabolismo , Sinapsis/metabolismo , Adenosina/farmacología , Animales , Animales Recién Nacidos , Agonistas de los Canales de Calcio/farmacología , Proteínas de Unión al Calcio/química , Proteínas de Unión al Calcio/farmacología , Proteínas Portadoras/farmacología , Quelantes/farmacología , Complemento C2/farmacología , Complemento C2a , Interacciones Farmacológicas , Ácido Egtácico/farmacología , Estimulación Eléctrica , Hipocampo/fisiología , Técnicas In Vitro , Glicoproteínas de Membrana/química , Glicoproteínas de Membrana/farmacología , Proteínas del Tejido Nervioso/química , Proteínas del Tejido Nervioso/efectos de los fármacos , Proteínas del Tejido Nervioso/farmacología , Proteínas del Tejido Nervioso/fisiología , Neuronas/efectos de los fármacos , Neuronas/fisiología , Técnicas de Placa-Clamp/métodos , Ratas , Ratas Sprague-Dawley , Receptores AMPA/química , Receptores AMPA/metabolismo , Proteínas SNARE , Sinapsis/efectos de los fármacos , Transmisión Sináptica/efectos de los fármacos , Transmisión Sináptica/fisiología , Sinaptotagminas , Proteínas de Transporte Vesicular/química , Proteínas de Transporte Vesicular/farmacología
4.
Clin Immunol Immunopathol ; 59(1): 65-71, 1991 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-2019011

RESUMEN

Complement-mediated precipitation inhibiting (CMPI) activity of sera of 5 individuals homozygous for C2 B was compared to that of sera of 20 individuals carrying the common C2 C allotype. Sera with the rare C2 B allotype had a depressed CMPI capacity in both the early (5 min) and the late (60 min) stages of the reaction. We have also compared the CMPI activity of seven homozygous C4A deficient (C4A*Q0) and eight C4B deficient (C4B*Q0) serum samples and did not find significant differences from the controls (no C4 null alleles) in any stage of the reaction. These results indicate that C2 is the critical component in the CMPI reaction of the two constituents of the classical pathway C3 convertase and that C2 B is less active than C2 C.


Asunto(s)
Reacciones Antígeno-Anticuerpo/efectos de los fármacos , Complemento C2/farmacología , Factor B del Complemento/inmunología , Complemento C2/inmunología , Complemento C2b , Complemento C4a/farmacología , Complemento C4b/farmacología , Vía Clásica del Complemento/efectos de los fármacos , Humanos , Inmunidad/efectos de los fármacos , Técnicas In Vitro
5.
Biochem J ; 271(3): 749-54, 1990 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-2244876

RESUMEN

The assembly of the classical-pathway C3 convertase from C4 and I2-treated C2 by the action of C1s is an Mg2(+)-dependent reaction. The Mg2+ concentration necessary for the assembly of C3 convertase in the fluid phase was found to be dependent on NaCl concentration. In the absence of NaCl more than 5 mM-MgCl2 was found to be required, whereas 0.5 mM-MgCl2 was adequate for the assembly of C3 convertase in the presence of 150 mM-NaCl. The C3 convertase assembled in a low-ionic-strength buffer was extremely labile compared with that assembled in buffer of physiological ionic strength, and the stability of C3 convertase was improved with the increase in NaCl concentration. It was found that the stabilizing effect of NaCl on C3 convertase was due to inhibition of the dissociating activity of C2b, which was formed during the assembly of C3 convertase. In addition to the dissociation-accelerating effect, C2b inhibited the assembly of C3 convertase in low-ionic-strength buffer, and this effect also was diminished with increase in NaCl concentration. An increase in NaCl concentration to more than 200 mM resulted in a decrease in the assembly of C3 convertase. This effect was not due to the lability of the assembled C3 convertase but due rather to the inhibition of C2 cleavage by C1s. Purified C3 convertase itself is stable in dilute medium or high-ionic-strength medium such as 500 mM-NaCl, suggesting that the interactions between C4b and C2a are hydrophobic. In these respects C2b seemed to be functionally similar to C4bp, but C2b failed to act as a cofactor for the Factor I-catalysed C4b cleavage.


Asunto(s)
Convertasas de Complemento C3-C5/metabolismo , Vía Clásica del Complemento/efectos de los fármacos , Cloruro de Sodio/farmacología , Complemento C2/farmacología , Complemento C2b , Convertasas de Complemento C3-C5/biosíntesis , Complemento C4b/metabolismo , Vía Clásica del Complemento/fisiología , Estabilidad de Enzimas/efectos de los fármacos , Fibrinógeno/metabolismo , Humanos , Magnesio/farmacología , Concentración Osmolar
6.
J Gen Virol ; 66 ( Pt 1): 121-9, 1985 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-2981956

RESUMEN

In the absence of virus-specific antibody, Ross River virus failed to activate either the classical or alternative complement pathways. Instead, it inhibited the cleavage of C3 via both pathways. The virus did not appear to act by disrupting C3bBb complexes or by preventing cleavage of factor B by factor D. Instead Ross River virus was found to interfere with the actual cleavage of C3 by activated factor B (C3bBb) of the alternative pathway and C4b2a of the classical pathway.


Asunto(s)
Alphavirus/fisiología , Proteínas del Sistema Complemento/inmunología , Virus del Río Ross/fisiología , Animales , Activación de Complemento , Complemento C2/farmacología , Complemento C3/metabolismo , Cobayas , Hemólisis , Humanos , Virus del Río Ross/crecimiento & desarrollo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...